Ftse Mib
34.249,77
0,91%
DAX
18.161,01
1,32%
S&P 500
5.099,96
1,02%
NASDAQ Composite
15.927,90
2,03%
Bitcoin
63.322,57
-0,65%

Quotazioni in diretta

Non abbiamo trovato risultati per:
Assicurati di aver scritto correttamente o prova ad allargare la ricerca.

Più Attivi

Toplist

Sembra che tu non sia connesso.
Clicca il pulsante qui sotto per accedere e visualizzare la tua cronologia recente.

Registrati

Sei già registrato? Accedi

Pepperstone

Inizia Ora

Pepperstone
Assistenza
Home Investire Azioni U.S.A. NASDAQ Aurinia Pharmaceuticals Inc (AUPH) Aurinia Pharmaceuticals Inc (AUPH) Notizie

Aurinia Pharmaceuticals Inc

AUPH
4,9001
0,0301 (0,62%)
27 Apr 2024 - Chiuso
Dati in Delay di 15 minuti
Borsa: NASDAQ
Tipo: Azione
Valuta: USD

Ultime notizie

Data Ora Fonte Titolo
16/4/202416:48BWUPDATE: New Aurinia Presentation Details at the 2024 Bloom..
15/4/202412:00BWAurinia Pharmaceuticals to Release First Quarter Financial..
09/4/202412:00BWAurinia Will Attend 2024 Bloom Burton & Co. Healthcare..
07/3/202422:44EDGAR2Form 4 - Statement of changes in beneficial ownership of..
07/3/202422:43EDGAR2Form 4 - Statement of changes in beneficial ownership of..
07/3/202422:42EDGAR2Form 4 - Statement of changes in beneficial ownership of..
07/3/202422:41EDGAR2Form 4 - Statement of changes in beneficial ownership of..
29/2/202422:10EDGAR2Form 8-K - Current report
29/2/202414:30BWAurinia Receives Exemptive Relief from Canadian Securities..
27/2/202414:30BWAurinia to Participate in Upcoming Investor Healthcare..
22/2/202422:35EDGAR2Form 4 - Statement of changes in beneficial ownership of..
22/2/202422:33EDGAR2Form 4 - Statement of changes in beneficial ownership of..
22/2/202422:31EDGAR2Form 4 - Statement of changes in beneficial ownership of..
22/2/202422:29EDGAR2Form 4 - Statement of changes in beneficial ownership of..
22/2/202422:27EDGAR2Form 4 - Statement of changes in beneficial ownership of..
22/2/202422:19EDGAR2Form 4/A - Statement of changes in beneficial ownership of..
15/2/202412:16EDGAR2Form 10-K - Annual report [Section 13 and 15(d), not S-K..
15/2/202412:06EDGAR2Form 8-K - Current report
15/2/202412:00BWAurinia Discloses 2023 Year-End Financial and Operational..
14/2/202421:27EDGAR2Form SC 13G - Statement of acquisition of beneficial..
05/2/202414:30BWAurinia Pharmaceuticals to Release 2023 Fourth Quarter and..
05/1/202412:02EDGAR2Form 8-K - Current report
05/1/202412:00BWAurinia Provides Preliminary Unaudited Fourth Quarter and..
20/12/202312:00BWAurinia Submits IND Application to US Food & Drug..
13/11/202312:00BWAurinia Pharmaceuticals Announces Collaboration Partner..
07/11/202316:30BWAurinia Presents Breadth of Data from AURORA Clinical..
02/11/202323:00BWAurinia Presents Breadth of Data at ASN 2023 Demonstrating..
02/11/202311:05EDGAR2Form 10-Q - Quarterly report [Sections 13 or 15(d)]
02/11/202311:01EDGAR2Form 8-K - Current report
02/11/202311:00BWAurinia Pharmaceuticals Reports Third Quarter and Nine..
26/10/202321:00BWAurinia Response in Support of 2023 Updated EULAR..
19/10/202316:31BWCORRECTING and REPLACING Aurinia Pharmaceuticals to Release..
19/10/202312:00BWAurinia Pharmaceuticals to Release Third Quarter Financial..
13/10/202318:00BWAurinia Pharmaceuticals Announces Presentations at American..
22/9/202322:36EDGAR2Form 4 - Statement of changes in beneficial ownership of..
21/9/202322:06EDGAR2Form 8-K - Current report
21/9/202312:00BWAurinia Board of Directors Appoints Dr. Robert T. Foster as..
21/8/202322:19EDGAR2Form 4 - Statement of changes in beneficial ownership of..
21/8/202322:11EDGAR2Form 8-K - Current report
21/8/202312:00BWAurinia Appoints Two New Board Directors with Deep..
03/8/202312:07EDGAR2Form 10-Q - Quarterly report [Sections 13 or 15(d)]
03/8/202312:03EDGAR2Form 8-K - Current report
03/8/202312:00BWAurinia Pharmaceuticals Reports Second Quarter and Six..
20/7/202312:00BWAurinia Pharmaceuticals to Release Second Quarter Financial..
19/7/202318:05BWLong Term Phase 3 Data Published in Arthritis & Rheumatology..
06/7/202314:33EDGAR2Form PX14A6G - Notice of exempt solicitation submitted by..
03/7/202312:06EDGAR2Form 8-K - Current report
29/6/202322:05BWAurinia Board of Directors Announces Exploration of..
20/6/202315:00BWAurinia Showcases Three Oral Presentations for LUPKYNIS®..
01/6/202315:00BWLUPKYNIS® (voclosporin) Achieved Significantly Higher Renal..
Apertura: 4,89 Min: 4,86 Max: 5,01
Chiusura: 4,87

La tua Cronologia

NASDAQ
AUPH
Aurinia Pharmaceuticals
Delayed Upgrade Clock

Il sito ADVFN Italia è stato realizzato ed è gestito da PRODESFIN su licenza di ADVFN PLC.

PER CONTATTI E PUBBLICITA' CLICCA QUI

Accedendo ai servizi offerti da ADVFN, ne si accettano le condizioni generali Termini & Condizioni

ADVFN Network